SI2154967T1 - Derivati pirimidina - Google Patents

Derivati pirimidina

Info

Publication number
SI2154967T1
SI2154967T1 SI200831203T SI200831203T SI2154967T1 SI 2154967 T1 SI2154967 T1 SI 2154967T1 SI 200831203 T SI200831203 T SI 200831203T SI 200831203 T SI200831203 T SI 200831203T SI 2154967 T1 SI2154967 T1 SI 2154967T1
Authority
SI
Slovenia
Prior art keywords
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
SI200831203T
Other languages
English (en)
Slovenian (sl)
Inventor
Wei-Guo Su
Hong Jia
Weihan Zhang
Yumin Cui
Xiaoqiang Yan
Yongxin Ren
Jifeng Duan
Yang Sai
Original Assignee
Hutchison Medipharma Enterprises Limited Offshore Group Chambers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Enterprises Limited Offshore Group Chambers filed Critical Hutchison Medipharma Enterprises Limited Offshore Group Chambers
Publication of SI2154967T1 publication Critical patent/SI2154967T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200831203T 2007-04-16 2008-04-15 Derivati pirimidina SI2154967T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91192107P 2007-04-16 2007-04-16
PCT/US2008/060366 WO2008128231A1 (fr) 2007-04-16 2008-04-15 Dérivés de pyrimidine
EP08745881.6A EP2154967B9 (fr) 2007-04-16 2008-04-15 Dérivés de pyrimidine

Publications (1)

Publication Number Publication Date
SI2154967T1 true SI2154967T1 (sl) 2014-06-30

Family

ID=39854302

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831203T SI2154967T1 (sl) 2007-04-16 2008-04-15 Derivati pirimidina

Country Status (17)

Country Link
US (2) US8349859B2 (fr)
EP (1) EP2154967B9 (fr)
JP (1) JP5635398B2 (fr)
KR (1) KR101424847B1 (fr)
BR (1) BRPI0809715A2 (fr)
CA (1) CA2684470C (fr)
DK (1) DK2154967T5 (fr)
ES (1) ES2465673T3 (fr)
HR (1) HRP20140377T2 (fr)
MX (1) MX2009011199A (fr)
NZ (1) NZ580671A (fr)
PL (1) PL2154967T3 (fr)
PT (1) PT2154967E (fr)
RU (1) RU2455994C2 (fr)
SI (1) SI2154967T1 (fr)
TW (1) TWI484960B (fr)
WO (1) WO2008128231A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药(上海)有限公司 一种化合物及其晶体
EP2395001A1 (fr) 2010-05-21 2011-12-14 Chemilia AB Nouveaux dérivés de pyrimidine
KR20130031296A (ko) 2010-05-21 2013-03-28 케밀리아 에이비 신규한 피리미딘 유도체
EP2433636A1 (fr) * 2010-09-27 2012-03-28 Medizinische Universität Wien Traitement de maladies malignes
EP2621276B1 (fr) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alcoxy pyrimidine inhibiteur de pde10
EP2502924A1 (fr) 2011-03-24 2012-09-26 Chemilia AB Nouveaux dérivés de pyrimidine
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
WO2013054351A1 (fr) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Composés hétérocycliques
EP2711365A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
EP2711364A1 (fr) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl ou benzimidazolyl)amino-2-(2-(indol-3-yl)éthyl)aminopyrimidines utiles pour le traitement du cancer
CN104955459B (zh) 2012-11-05 2019-02-01 南特知识产权控股有限责任公司 取代的吲哚-5-酚衍生物及其治疗应用
CA2906185A1 (fr) 2013-03-15 2014-09-18 Nantbioscience, Inc. Derives indol-5-ol substitues et leurs applications therapeutiques
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
WO2016137506A1 (fr) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Dérivés de pyrimidine comme inhibiteurs de kinase et applications thérapeutiques associées
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
WO2020253862A1 (fr) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 Inhibiteur du dérivé d'oxyde de phosphore aryle contenant de l'azote, son procédé de préparation et son utilisation
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2002016348A1 (fr) * 2000-08-09 2002-02-28 Astrazeneca Ab Derives bicycliques antiangiogeniques
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US20040092750A1 (en) * 2001-03-01 2004-05-13 Tomoyuki Hasegawa 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor
US20040171630A1 (en) * 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2003030909A1 (fr) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
US20060252943A1 (en) 2002-06-17 2006-11-09 Amogh Boloor Chemical process
ATE451104T1 (de) * 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
CA2488739A1 (fr) * 2002-08-30 2004-03-11 Eisai Co., Ltd. Derives aromatiques contenant de l'azote
WO2004032882A2 (fr) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Composes chimiques
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8084457B2 (en) * 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
CN100584832C (zh) * 2003-09-18 2010-01-27 诺瓦提斯公司 可用于治疗增殖性病症的2,4-二(苯基氨基)嘧啶类
CA2545711A1 (fr) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'uree en tant que modulateurs de la kinase
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
MXPA06007242A (es) 2003-12-23 2006-08-18 Pfizer Nuevos derivados de quinolina.
DE102004044556A1 (de) * 2004-09-15 2006-03-30 Bayer Healthcare Ag Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren
TW200628463A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
CA2587590A1 (fr) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Composes de pyrimidine et leurs utilisations
WO2006071079A1 (fr) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline employés dans l'inhibition de la croissance des cellules cancéreuses et méthodes de synthèse desdits dérivés
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
EP1890703B1 (fr) 2005-06-14 2016-05-11 Taigen Biotechnology Composes pyrimidine en tant qu'inhibiteurs des recepteurs chemokine
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors

Also Published As

Publication number Publication date
TW200848049A (en) 2008-12-16
HRP20140377T1 (en) 2014-05-23
PL2154967T3 (pl) 2014-08-29
JP5635398B2 (ja) 2014-12-03
EP2154967B9 (fr) 2014-07-23
EP2154967A4 (fr) 2010-05-19
BRPI0809715A2 (pt) 2019-11-05
CA2684470A1 (fr) 2008-10-23
NZ580671A (en) 2012-03-30
EP2154967B1 (fr) 2014-03-05
WO2008128231A1 (fr) 2008-10-23
US20080255172A1 (en) 2008-10-16
US20130065890A1 (en) 2013-03-14
EP2154967A1 (fr) 2010-02-24
ES2465673T9 (es) 2014-11-14
AU2008240084A1 (en) 2008-10-23
RU2009141982A (ru) 2011-05-27
KR101424847B1 (ko) 2016-07-08
US8349859B2 (en) 2013-01-08
CA2684470C (fr) 2016-02-09
MX2009011199A (es) 2010-03-17
US8901143B2 (en) 2014-12-02
TWI484960B (zh) 2015-05-21
DK2154967T5 (en) 2014-11-17
DK2154967T3 (da) 2014-04-07
JP2010524952A (ja) 2010-07-22
PT2154967E (pt) 2014-06-05
KR20100016592A (ko) 2010-02-12
HRP20140377T2 (hr) 2015-01-16
ES2465673T3 (es) 2014-06-06
RU2455994C2 (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
HRP20140377T1 (en) Pyrimidine derivatives
ZA201003875B (en) Novel pyrimidine derivatives
HK1203488A1 (en) Pyrimidine substituted purine derivatives
ZA200806153B (en) Pyrimidine derivatives
GB0614579D0 (en) Pyrimidine derivatives
HK1149756A1 (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
EP2120569A4 (fr) Dérivés spirochromanone
IL210176A0 (en) Substituted pyrimidone derivatives
IL202020A0 (en) Spiroindolinone derivatives
ZA201001058B (en) Quinazolinamide derivatives
ZA201000431B (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
ZA201000107B (en) Pyrimidine derivatives 934
IL202667A0 (en) Isoxazole-imidazole derivatives
HK1215434A1 (zh) 取代的嘧啶衍生物
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2094704A4 (fr) Dérivés de pyrimidinone substitués par cis-cyclohexyle
EP2133347A4 (fr) Dérivés de 1-biarylazétidinone
HK1141009A1 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
HK1146276A1 (en) Thiadiazinone derivatives
EP2204368A4 (fr) Dérivés de 4-sulfonylpipéridine
ZA201000311B (en) Sulfonyl-quinoline derivatives